ClinicalTrials.gg
Active, not recruitingNCT02489318TITANUpdated Nov 4, 2026Results posted

A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC

A Phase 3 interventional study of Apalutamide and Placebo in Prostate Cancer, sponsored by Aragon Pharmaceuticals, Inc.. Active, not recruiting at 220 sites in 22 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Aragon Pharmaceuticals, Inc. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,052
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 70 studies testing apalutamide in Prostatic Neoplasms — 14 open to participants now, 36 under way, 12 of them phase 3. apalutamide · Prostatic Neoplasms.

Enrollment
5th of 70
1,052 · median 81
Started
2015
with 2 others
Phase 3
16 of 70
2 open now
Primary completion
2020-09
later than 4 of 35 live
Registered
8th of 70
by date
Lead sponsor
9 of 70
Aragon Pharmaceuticals, Inc.

Among the 70 studies testing apalutamide in Prostatic Neoplasms, this one is the 5th largest by enrollment, is one of 3 that started in 2015, is one of 16 in phase 3, reaches primary completion later than 4 of the 35 other live ones, and was the 8th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

14 of the 70 studies testing apalutamide in Prostatic Neoplasms are open now, in 11 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About apalutamide

apalutamide: first FDA approval 2018 (ERLEADA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing apalutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to determine if the addition of apalutamide to ADT provides superior efficacy in improving radiographic progression-free survival (rPFS) or overall survival (OS) for participants with mHSPC.

Read the detailed description

This is a randomized (study medication assigned to participants by chance), double-blind (neither the researchers nor the participants know what treatment the participant is receiving), placebo-controlled, multinational, multicenter study of apalutamide in participants with mHSPC. The study consists of 4 Phases: Screening Phase (up to 28 days before randomization), Treatment Phase (28 day treatment cycles until disease progression or the occurrence of unacceptable treatment related toxicity), an End of Treatment Phase (until 30 days after the last dose of study drug), and then a Survival Follow up Phase. In the event of a positive study result and notification of unblinding at either of the interim analyses or at the final analysis, participants in the treatment Phase will have the opportunity to enroll in an Open-label Extension Phase, which will allow participants to receive active drug (apalutamide) for approximately 3 years. Participants who are receiving apalutamide in the Open-label Extension Phase may continue receiving apalutamide in the Long-term Extension (LTE) Phase if they will continue to derive benefit from treatment (based on investigator assessment). Participants' safety will be monitored throughout the study.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • Prostate Cancer
  • JNJ-56021927
  • Androgen Deprivation Therapy
  • ARN-509
  • Apalutamide
  • TITAN
  • Metastatic Hormone-sensitive Prostate Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of prostate adenocarcinoma as confirmed by the investigator
  • disease documented by greater than or equal to (>=) 1 bone lesions on 99mTc bone scan. Participants with a single bone lesion must have confirmation of bone metastasis by computed tomography (CT) or magnetic resonance imaging (MRI)
  • Performance Status (ECOG PS) grade of 0 or 1
  • Participants who received docetaxel treatment must meet the following criteria: a) Received a maximum of 6 cycles of docetaxel therapy for mHSPC; b) Received the last dose of docetaxel \<=2 months prior to randomization; c) Maintained a response to docetaxel of stable disease or better, by investigator assessment of imaging and PSA, prior to randomization
  • Other allowed prior treatment for mHSPC: a) Maximum of 1 course of radiation or surgical intervention; radiation therapy for metastatic lesions must be completed prior to randomization; b) Less than or equal to (\<=) 6 months of ADT prior to randomization
  • Allowed prior treatments for localized prostate cancer (all treatments must have been completed >= 1 year prior to randomization) a) \<= 3 years total of ADT; b) All other forms of prior therapies including radiation therapy, prostatectomy,lymph node dissection, and systemic therapies

Exclusion criteria

Exclusion Criteria:

  • Pathological finding consistent with small cell, ductal or neuroendocrine carcinoma of the prostate
  • Known
  • Lymph nodes as only sites of
  • Visceral (ie, liver or lung) metastases as only sites of metastases
  • Other prior less than or equal to 5 years prior to randomization with the exception of squamous or basal cell skin carcinoma or non-invasive superficial bladder cancer
  • Prior treatment with other next generation anti-androgens or other CYP17 inhibitors, immunotherapy or radiopharmaceutical agents for prostate cancer
  • History of seizures or medications known to lower seizure threshold
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
1,052 participants (actual)

Study arms

  • Experimental
    Apalutamide plus ADT

    Participants will receive apalutamide 240 milligram (mg) (4X 60 mg tablets) with ADT.

    Drug: Apalutamide · Drug: Androgen Deprivation Therapy (ADT)

  • Experimental
    Placebo plus ADT

    Participants will receive matching Placebo with ADT.

    Drug: Placebo · Drug: Androgen Deprivation Therapy (ADT)

Interventions

  • Participants will receive apalutamide 240 mg (4 x 60 mg) tablets orally once daily in each 28 day treatment cycles.

    Also known as: JNJ-56021927, ARN-509

  • DrugPlacebo

    Participants will receive Placebo orally once daily in each 28 day treatment cycles.

  • DrugAndrogen Deprivation Therapy (ADT)

    All participants will receive and remain on a stable regimen of ADT (gonadotropin releasing hormone analog \[GnRHa\] or surgical castration). The choice of the GnRHa (agonist or antagonist) will be at discretion of the Investigator. Dosing (dose and frequency of administration) will be consistent with the prescribing information.

06

What researchers measure

Primary outcomes

  1. Radiographic Progression-free Survival (rPFS)

    rPFS as assessed by the investigator was defined as the duration from the date of randomization to the date of first documentation of radiographic progressive disease or death due to any cause, whichever occurred first. Radiographic progressive disease was defined as progression of soft tissue lesions measured by computed tomography (CT) or magnetic resonance imaging (MRI) as defined by modified Response evaluation criteria in solid tumors (RECIST) 1.1.

    Time frame: Up to 35 months

  2. Overall Survival (OS)

    OS was defined as the time from date of randomization to date of death from any cause.

    Time frame: Up to 57 months

Secondary outcomes

  1. Time to Initiation of Cytotoxic Chemotherapy

    Time to initiation of cytotoxic chemotherapy was defined as the time from date of randomization to the date of initiation of cytotoxic chemotherapy for prostate cancer.

    Time frame: Up to 57 months

  2. Time to Pain Progression

    Time to pain progression was defined as the time from the date of randomization to the date of the first observation of pain progression. Pain progression was defined as an average increase by 2 points from baseline to greater than (\>) 4 on the Brief Pain Inventory - Short Form (BPI-SF) worst pain intensity (item 3) with no decrease in opioids confirmed greater than equal to (\>=) 3 weeks apart or initiation of chronic opioids, whichever occurred first. BPI-SF is a self-administered questionnaire developed to assess severity of pain and impact of pain on daily functions. Item 3 (worst pain intensity) asks participants to rate worst pain in prior 7-days on a 0-10 numeric rating scale, where "0" indicates "No pain" and "10" indicates "Pain as bad as you can imagine." A lower score is better.

    Time frame: Up to 57 months

  3. Time to Chronic Opioid Use

    Time to chronic opioid use was defined as the time from date of randomization to the first date of confirmed chronic opioid use. For participants entering the study without receiving opioids, chronic opioid use was defined as administration of opioid analgesics lasting for greater than or equal to (\>=) 3 weeks for oral or \>=7 days for non-oral formulations. For participants entering the study already receiving opioids, chronic opioid use was defined as a \>=30 percent (%) increase in total daily dose of the opioid analgesics lasting for \>= 3 weeks for oral or \>= 7 days for non-oral formulation.

    Time frame: Up to 57 months

  4. Time to Skeletal-related Event (SRE)

    Time to SRE was defined as the time from the date of randomization to the date of the first observation of an SRE. A SRE was defined as the occurrence of either a pathological fracture, or spinal cord compression, or radiation to bone, or surgery to bone.

    Time frame: Up to 57 months

07

Results

Posted Jan 18, 2022

Participant flow

Randomized
Participant flow — Randomized
MilestonePlacebo + Androgen Deprivation Therapy (ADT)Apalutamide + ADT
Started527525
Completed527524
Not completed01
Withdrew: Withdrawal by subject01
Treated
Participant flow — Treated
MilestonePlacebo + Androgen Deprivation Therapy (ADT)Apalutamide + ADT
Started527524
Completed2080
Not completed319524
Withdrew: Adverse event1962
Withdrew: Death1311
Withdrew: Physician decision46
Withdrew: Protocol violation12
Withdrew: Withdrawal by subject3736
Withdrew: Other: progressive disease245138
Withdrew: Other02
Withdrew: Ongoing0267

Outcome measures

PrimaryRadiographic Progression-free Survival (rPFS)

rPFS as assessed by the investigator was defined as the duration from the date of randomization to the date of first documentation of radiographic progressive disease or death due to any cause, whichever occurred first. Radiographic progressive disease was defined as progression of soft tissue lesions measured by computed tomography (CT) or magnetic resonance imaging (MRI) as defined by modified Response evaluation criteria in solid tumors (RECIST) 1.1.

Time frame:
Up to 35 months
Reported as:
Median · months
Radiographic Progression-free Survival (rPFS)
monthsPlacebo + Androgen Deprivation Therapy (ADT)Apalutamide + ADT
Radiographic Progression-free Survival (rPFS)22.08 (18.46 to 32.92)NA (NA to NA)
Statistical analysis
  • Placebo + Androgen Deprivation Therapy (ADT) vs Apalutamide + ADT · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.484 · 95% CI 0.391 to 0.600
PrimaryOverall Survival (OS)

OS was defined as the time from date of randomization to date of death from any cause.

Time frame:
Up to 57 months
Reported as:
Median · months
Overall Survival (OS)
monthsPlacebo + Androgen Deprivation Therapy (ADT)Apalutamide + ADT
Overall Survival (OS)52.17 (41.86 to NA)NA (NA to NA)
Statistical analysis
  • Placebo + Androgen Deprivation Therapy (ADT) vs Apalutamide + ADT · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.651 · 95% CI 0.534 to 0.793
SecondaryTime to Initiation of Cytotoxic Chemotherapy

Time to initiation of cytotoxic chemotherapy was defined as the time from date of randomization to the date of initiation of cytotoxic chemotherapy for prostate cancer.

Time frame:
Up to 57 months
Reported as:
Median · months
Time to Initiation of Cytotoxic Chemotherapy
monthsPlacebo + Androgen Deprivation Therapy (ADT)Apalutamide + ADT
Time to Initiation of Cytotoxic ChemotherapyNA (NA to NA)NA (NA to NA)
Statistical analysis
  • Placebo + Androgen Deprivation Therapy (ADT) vs Apalutamide + ADT · Log Rank · p = <.0001 · Hazard ratio (hr): 0.469 · 95% CI 0.350 to 0.630
SecondaryTime to Pain Progression

Time to pain progression was defined as the time from the date of randomization to the date of the first observation of pain progression. Pain progression was defined as an average increase by 2 points from baseline to greater than (\>) 4 on the Brief Pain Inventory - Short Form (BPI-SF) worst pain intensity (item 3) with no decrease in opioids confirmed greater than equal to (\>=) 3 weeks apart or initiation of chronic opioids, whichever occurred first. BPI-SF is a self-administered questionnaire developed to assess severity of pain and impact of pain on daily functions. Item 3 (worst pain intensity) asks participants to rate worst pain in prior 7-days on a 0-10 numeric rating scale, where "0" indicates "No pain" and "10" indicates "Pain as bad as you can imagine." A lower score is better.

Time frame:
Up to 57 months
Reported as:
Median · months
Time to Pain Progression
monthsPlacebo + Androgen Deprivation Therapy (ADT)Apalutamide + ADT
Time to Pain ProgressionNA (51.32 to NA)NA (NA to NA)
Statistical analysis
  • Placebo + Androgen Deprivation Therapy (ADT) vs Apalutamide + ADT · Log Rank · p = 0.1966 · Hazard ratio (hr): 0.868 · 95% CI 0.700 to 1.076
SecondaryTime to Chronic Opioid Use

Time to chronic opioid use was defined as the time from date of randomization to the first date of confirmed chronic opioid use. For participants entering the study without receiving opioids, chronic opioid use was defined as administration of opioid analgesics lasting for greater than or equal to (\>=) 3 weeks for oral or \>=7 days for non-oral formulations. For participants entering the study already receiving opioids, chronic opioid use was defined as a \>=30 percent (%) increase in total daily dose of the opioid analgesics lasting for \>= 3 weeks for oral or \>= 7 days for non-oral formulation.

Time frame:
Up to 57 months
Reported as:
Median · months
Time to Chronic Opioid Use
monthsPlacebo + Androgen Deprivation Therapy (ADT)Apalutamide + ADT
Time to Chronic Opioid UseNA (51.32 to NA)NA (NA to NA)
Statistical analysis
  • Placebo + Androgen Deprivation Therapy (ADT) vs Apalutamide + ADT · Log Rank · p = 0.1563 · Hazard ratio (hr): 0.794 · 95% CI 0.576 to 1.094
SecondaryTime to Skeletal-related Event (SRE)

Time to SRE was defined as the time from the date of randomization to the date of the first observation of an SRE. A SRE was defined as the occurrence of either a pathological fracture, or spinal cord compression, or radiation to bone, or surgery to bone.

Time frame:
Up to 57 months
Reported as:
Median · months
Time to Skeletal-related Event (SRE)
monthsPlacebo + Androgen Deprivation Therapy (ADT)Apalutamide + ADT
Time to Skeletal-related Event (SRE)NA (51.78 to NA)NA (NA to NA)
Statistical analysis
  • Placebo + Androgen Deprivation Therapy (ADT) vs Apalutamide + ADT · Log Rank · p = 0.3608 · Hazard ratio (hr): 0.857 · 95% CI 0.615 to 1.194

Adverse events

Collected over Up to 57 months. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo + Androgen Deprivation Therapy (ADT)35/527 (6.6%)115/527 (21.8%)485/527 (92%)
Placebo + ADT to Apalutamide + ADT10/208 (4.8%)29/208 (13.9%)153/208 (73.6%)
Apalutamide + ADT31/524 (5.9%)153/524 (29.2%)494/524 (94.3%)
Most frequent serious events
Showing 10 of 234
Most frequent serious events
EventPlacebo + Androgen Deprivation Therapy (ADT)Placebo + ADT to Apalutamide + ADTApalutamide + ADT
PneumoniaInfections and infestations3/5273/20810/524
HaematuriaRenal and urinary disorders3/5271/20810/524
Urinary RetentionRenal and urinary disorders9/5270/2084/524
Myocardial InfarctionCardiac disorders0/5270/2088/524
Cerebrovascular AccidentNervous system disorders1/5273/2084/524
AnaemiaBlood and lymphatic system disorders6/5270/2081/524
Back PainMusculoskeletal and connective tissue disorders6/5270/2084/524
Spinal Cord CompressionNervous system disorders6/5270/2082/524
Non-Cardiac Chest PainGeneral disorders1/5272/2080/524
SepsisInfections and infestations2/5272/2080/524
Most frequent other events
Showing 10 of 84
Most frequent other events
EventPlacebo + Androgen Deprivation Therapy (ADT)Placebo + ADT to Apalutamide + ADTApalutamide + ADT
Hot FlushVascular disorders87/5273/208121/524
Back PainMusculoskeletal and connective tissue disorders108/52711/208106/524
FatigueGeneral disorders87/52715/208107/524
RashSkin and subcutaneous tissue disorders23/52726/208106/524
ArthralgiaMusculoskeletal and connective tissue disorders82/52715/208101/524
HypertensionVascular disorders84/52713/208100/524
Weight IncreasedInvestigations92/5277/20855/524
AnaemiaBlood and lymphatic system disorders71/52713/20868/524
Pain in ExtremityMusculoskeletal and connective tissue disorders67/5278/20869/524
ConstipationGastrointestinal disorders57/5276/20858/524

Baseline characteristics

Age, Continuous
Age, Continuous(years)Placebo + Androgen Deprivation Therapy (ADT)Apalutamide + ADTTotal
Mean67.9 ± 8.4268.9 ± 8.1168.4 ± 8.28
Sex: Female, Male
Sex: Female, Male(Participants)Placebo + Androgen Deprivation Therapy (ADT)Apalutamide + ADTTotal
Female000
Male5275251052
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo + Androgen Deprivation Therapy (ADT)Apalutamide + ADTTotal
American Indian or Alaska Native11617
Asian112119231
Native Hawaiian or Other Pacific Islander000
Black or African American91019
White365354719
More than one race011
Unknown or Not Reported303565
Region of Enrollment
Region of Enrollment(participants)Placebo + Androgen Deprivation Therapy (ADT)Apalutamide + ADTTotal
ARGENTINA201737
AUSTRALIA5611
BRAZIL385492
CANADA161430
CHINA464894
CZECH REPUBLIC121931
FRANCE8816
GERMANY10717
HUNGARY111324
ISRAEL8614
ITALY181634
JAPAN232851
MEXICO252348
POLAND12719
ROMANIA7411
RUSSIAN FEDERATION6665131
SOUTH KOREA413576
SPAIN12820
SWEDEN8816
TURKEY222850
UKRAINE6042102
UNITED KINGDOM162036
UNITED STATES434992
Race (NIH/OMB)
Race (NIH/OMB)(participants)Placebo + Androgen Deprivation Therapy (ADT)Apalutamide + ADTTotal
American Indian or Alaska Native11617
Asian112119231
Black or African American91019
More than one race011
Not Reported81119
Other222446
White365354719
08

Study locations

220 sites
  • Homewood, Alabama, United States
  • Tucson, Arizona, United States
  • San Bernardino, California, United States
  • San Diego, California, United States
  • Denver, Colorado, United States
  • Norwalk, Connecticut, United States
  • Fort Myers, Florida, United States
  • Chicago, Illinois, United States
  • Fort Wayne, Indiana, United States
  • Jeffersonville, Indiana, United States
  • New Orleans, Louisiana, United States
  • Baltimore, Maryland, United States
  • Rockville, Maryland, United States
  • Lansing, Michigan, United States
  • Troy, Michigan, United States
  • Omaha, Nebraska, United States
  • Las Vegas, Nevada, United States
  • Brooklyn, New York, United States
  • Poughkeepsie, New York, United States
  • Syracuse, New York, United States
  • The Bronx, New York, United States
  • Raleigh, North Carolina, United States
  • Salisbury, North Carolina, United States
  • Cleveland, Ohio, United States
  • Middleburg Heights, Ohio, United States
  • Springfield, Oregon, United States
  • Bala-Cynwyd, Pennsylvania, United States
  • Bryn Mawr, Pennsylvania, United States
  • Lancaster, Pennsylvania, United States
  • Charleston, South Carolina, United States
  • Nashville, Tennessee, United States
  • Dallas, Texas, United States
  • Houston, Texas, United States
  • San Antonio, Texas, United States
  • Richmond, Virginia, United States
  • Virginia Beach, Virginia, United States
  • Burien, Washington, United States
  • Spokane, Washington, United States
  • Milwaukee, Wisconsin, United States
  • Berazategui, Argentina
  • Buenos Aires, Argentina
  • C.a.b.a., Argentina
  • Capital Federal, Argentina
  • Ciudad Automoma Buenos Aires, Argentina
  • Ciudad de Buenos Aires, Argentina
  • Córdoba, Argentina
  • La Plata, Argentina
  • Pergamino, Argentina
  • Rosario, Argentina
  • San Miguel de Tucumán, Argentina
  • San Salvador de Jujuy, Argentina
  • Albury, Australia
  • Elizabeth Vale, Australia
  • Kogarah, Australia
  • Port Macquarie, Australia
  • South Brisbane, Australia
  • St Leonards, Australia
  • Barretos, Brazil
  • Florianópolis, Brazil
  • Goiânia, Brazil
  • Ijuí, Brazil
  • Natal, Brazil
  • Ribeirão Preto, Brazil
  • Rio de Janeiro, Brazil
  • Salvador, Brazil
  • Santo André, Brazil
  • São Paulo, Brazil
  • Sorocaba, Brazil
  • Calgary, Alberta, Canada
  • Vancouver, British Columbia, Canada
  • Hamilton, Ontario, Canada
  • Kingston, Ontario, Canada
  • Toronto, Ontario, Canada
  • Québec, Quebec, Canada
  • Beijing, China
  • Chengdu, China
  • Chongqing, China
  • Fuzhou, China
  • Guangzhou, China
  • Hangzhou, China
  • Nanjing, China
  • Shanghai, China
  • Suzhou, China
  • Wuhan, China
  • Wuxi, China
  • Xi'an, China
  • Hradec Králove, Czechia
  • Liberec, Czechia
  • Nový Jicin, Czechia
  • Olomouc, Czechia
  • Opava, Czechia
  • Pardubice, Czechia
  • Prague, Czechia
  • Zlín, Czechia
  • Clermont-Ferrand, France
  • Montpellier, France
  • Nancy, France
  • Paris, France
  • Pierre-Bénite, France
  • Strasbourg, France

Showing the first 100 of 220 sites across 22 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Hori T, Iwamoto H, Inaba T, Nakagawa R, Kamijima T, Kano H, Makino T, Naito R, Yaegashi H, Shigehara K, Nohara T, Izumi K, Mizokami A. Association Between Castration-resistant Prostate Cancer Progression Patterns and Survival Outcomes in Metastatic Castration-sensitive Prostate Cancer: A Post Hoc Analysis of the TITAN Trial. Eur Urol Focus. 2026 Sep 11:S2405-4569(26)00149-5. doi: 10.1016/j.euf.2026.07.003. Online ahead of print. PubMed 42728112 ↗
  • Hori T, Iwamoto H, Inaba T, Nakagawa R, Kamijima T, Makino T, Naito R, Kadomoto S, Yaegashi H, Shigehara K, Nohara T, Izumi K, Mizokami A. Integrating NCCN and LATITUDE in metastatic castration-sensitive prostate cancer: a TITAN analysis. World J Urol. 2026 Aug 19;44(1):585. doi: 10.1007/s00345-026-06695-5. PubMed 42616151 ↗
  • Karsh LI, Bevans KB, Saad F, Chung BH, Oudard S, Brookman-May SD, McCarthy SA, Smith MR, Chi KN, Small EJ, Agarwal N. Prostate-specific antigen and health-related quality of life in individuals with advanced prostate cancer treated with apalutamide: a plain language summary of the SPARTAN and TITAN studies. Future Oncol. 2024;20(35):2689-2698. doi: 10.1080/14796694.2024.2384257. Epub 2024 Aug 20. PubMed 39163505 ↗
  • Roy S, Sun Y, Chi KN, Ong M, Malone S, Wallis CJD, Kishan AU, Malone J, Swami U, Gebrael G, Brown JR, Jia AY, Morgan SC, Saad F, Chowdhury S, Agarwal N, Spratt DE. Early Prostate-Specific Antigen Response by 6 Months Is Predictive of Treatment Effect in Metastatic Hormone Sensitive Prostate Cancer: An Exploratory Analysis of the TITAN Trial. J Urol. 2024 Nov;212(5):672-681. doi: 10.1097/JU.0000000000004158. Epub 2024 Jul 26. PubMed 39058790 ↗
  • Merseburger AS, Agarwal N, Bjartell A, Uemura H, Soto AJ, Bhaumik A, Bohm J, Tran N, Krochmann N, Nematian-Samani M, Mundle SD, Brookman-May SD, Lopez-Gitlitz A, McCarthy SA, Chi K, Chowdhury S. Targeted Investigational Treatment Analysis of Novel Anti-androgen (TITAN) study: ultralow prostate-specific antigen decline with apalutamide plus androgen-deprivation therapy. BJU Int. 2024 Dec;134(6):982-991. doi: 10.1111/bju.16449. Epub 2024 Jun 28. PubMed 38940282 ↗
  • Shen J, Chowdhury S, Agarwal N, Karsh LI, Oudard S, Gartrell BA, Feyerabend S, Saad F, Pieczonka CM, Chi KN, Brookman-May SD, Rooney B, Bhaumik A, McCarthy SA, Bevans KB, Mundle SD, Small EJ, Smith MR, Graff JN. Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN. Br J Cancer. 2024 Jan;130(1):73-81. doi: 10.1038/s41416-023-02492-8. Epub 2023 Nov 11. PubMed 37951974 ↗
  • Merseburger AS, Agarwal N, Bhaumik A, Lefresne F, Karsh LI, Pereira de Santana Gomes AJ, Soto AJ, Given RW, Brookman-May SD, Mundle SD, McCarthy SA, Uemura H, Chowdhury S, Chi KN, Bjartell A. Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: A subgroup analysis of the randomised clinical TITAN study. Eur J Cancer. 2023 Nov;193:113290. doi: 10.1016/j.ejca.2023.113290. Epub 2023 Aug 11. PubMed 37708629 ↗
  • Agarwal N, McQuarrie K, Bjartell A, Chowdhury S, Pereira de Santana Gomes AJ, Chung BH, Ozguroglu M, Juarez Soto A, Merseburger AS, Uemura H, Ye D, Given R, Basch E, Miladinovic B, Lopez-Gitlitz A, Chi KN. Apalutamide plus Androgen Deprivation Therapy for Metastatic Castration-Sensitive Prostate Cancer: Analysis of Pain and Fatigue in the Phase 3 TITAN Study. J Urol. 2021 Oct;206(4):914-923. doi: 10.1097/JU.0000000000001841. Epub 2021 May 27. PubMed 34039013 ↗
  • Chi KN, Chowdhury S, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, Juarez A, Merseburger AS, Ozguroglu M, Uemura H, Ye D, Brookman-May S, Mundle SD, McCarthy SA, Larsen JS, Sun W, Bevans KB, Zhang K, Bandyopadhyay N, Agarwal N. Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study. J Clin Oncol. 2021 Jul 10;39(20):2294-2303. doi: 10.1200/JCO.20.03488. Epub 2021 Apr 29. PubMed 33914595 ↗
  • Uemura H, Koroki Y, Iwaki Y, Imanaka K, Kambara T, Lopez-Gitlitz A, Smith A, Uemura H. Skin rash following Administration of Apalutamide in Japanese patients with Advanced Prostate Cancer: an integrated analysis of the phase 3 SPARTAN and TITAN studies and a phase 1 open-label study. BMC Urol. 2020 Sep 2;20(1):139. doi: 10.1186/s12894-020-00689-0. PubMed 32878613 ↗
  • Agarwal N, McQuarrie K, Bjartell A, Chowdhury S, Pereira de Santana Gomes AJ, Chung BH, Ozguroglu M, Juarez Soto A, Merseburger AS, Uemura H, Ye D, Given R, Cella D, Basch E, Miladinovic B, Dearden L, Deprince K, Naini V, Lopez-Gitlitz A, Chi KN; TITAN investigators. Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2019 Nov;20(11):1518-1530. doi: 10.1016/S1470-2045(19)30620-5. Epub 2019 Sep 29. PubMed 31578173 ↗
  • Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, Juarez Soto A, Merseburger AS, Ozguroglu M, Uemura H, Ye D, Deprince K, Naini V, Li J, Cheng S, Yu MK, Zhang K, Larsen JS, McCarthy S, Chowdhury S; TITAN Investigators. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med. 2019 Jul 4;381(1):13-24. doi: 10.1056/NEJMoa1903307. Epub 2019 May 31. PubMed 31150574 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2015 to primary completion in Sep 2020, 57 months.

Results were first posted in Jan 2022, 1 year 4 months after primary completion.

Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's 57 months is above that.

Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2015
First posted
Jul 3, 2015
StartActual
Nov 27, 2015
Primary completionActual
Sep 7, 2020
CompletionEst.
Dec 31, 2027
Results first posted
Jan 18, 2022
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42728112 ↗
Sep 28, 2026
Show all 2 updates
  1. Nov 4, 2026
    Minor edits only
    + 2 other changes: verification date and site details
  2. Sep 28, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42728112 ↗
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT02489318
Responsible party
Sponsor
First posted
Jul 3, 2015
Start date
Nov 27, 2015
Primary completion
Sep 7, 2020
Completion
Dec 31, 2027 (estimated)
Results posted
Jan 18, 2022
Last update
Nov 4, 2026

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apalutamide

Start the discussion